Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Disruptions in Liver Function among Cancer Patients and Patients Treated with Tyrosine Kinase Inhibiting Drugs: Comparisons of Two Population-Based Databases.

Landis SH, Nordstrom BL, Sansbury LB, Shantakumar S, Laurent SA, Fraeman KH, Nelson JJ.

J Cancer Epidemiol. 2013;2013:358285. doi: 10.1155/2013/358285. Epub 2013 Apr 21.

2.

Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.

Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, Fu AZ, Sansbury LB, Potosky AL.

Ann Oncol. 2013 Jun;24(6):1574-9. doi: 10.1093/annonc/mdt019. Epub 2013 Feb 20.

3.

Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer?

Brown DA, Hance KW, Rogers CJ, Sansbury LB, Albert PS, Murphy G, Laiyemo AO, Wang Z, Cross AJ, Schatzkin A, Danta M, Srasuebkul P, Amin J, Law M, Breit SN, Lanza E.

Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):337-46. doi: 10.1158/1055-9965.EPI-11-0786. Epub 2011 Dec 5.

4.

Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer.

Tippin BL, Levine AJ, Materi AM, Song WL, Keku TO, Goodman JE, Sansbury LB, Das S, Dai A, Kwong AM, Lin AM, Lin JM, Park JM, Patterson RE, Chlebowski RT, Garavito RM, Inoue T, Cho W, Lawson JA, Kapoor S, Kolonel LN, Le Marchand L, Haile RW, Sandler RS, Lin HJ.

Prostaglandins Other Lipid Mediat. 2012 Jan;97(1-2):22-8. doi: 10.1016/j.prostaglandins.2011.07.006. Epub 2011 Jul 28.

5.

Dietary lignan and proanthocyanidin consumption and colorectal adenoma recurrence in the Polyp Prevention Trial.

Bobe G, Murphy G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Cross AJ.

Int J Cancer. 2012 Apr 1;130(7):1649-59. doi: 10.1002/ijc.26184. Epub 2011 Aug 1.

6.

Do interleukin polymorphisms play a role in the prevention of colorectal adenoma recurrence by dietary flavonols?

Bobe G, Murphy G, Albert PS, Sansbury LB, Young MR, Lanza E, Schatzkin A, Colburn NH, Cross AJ.

Eur J Cancer Prev. 2011 Mar;20(2):86-95. doi: 10.1097/CEJ.0b013e3283429e45.

7.

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM.

J Natl Cancer Inst. 2010 Nov 17;102(22):1698-705. doi: 10.1093/jnci/djq390. Epub 2010 Oct 13.

8.

Serum cytokine concentrations, flavonol intake and colorectal adenoma recurrence in the Polyp Prevention Trial.

Bobe G, Murphy G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Colburn NH, Cross AJ.

Br J Cancer. 2010 Oct 26;103(9):1453-61. doi: 10.1038/sj.bjc.6605915. Epub 2010 Oct 5.

9.

Serum adiponectin, leptin, C-peptide, homocysteine, and colorectal adenoma recurrence in the Polyp Prevention Trial.

Bobe G, Murphy G, Rogers CJ, Hance KW, Albert PS, Laiyemo AO, Sansbury LB, Lanza E, Schatzkin A, Cross AJ.

Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1441-52. doi: 10.1158/1055-9965.EPI-09-1082. Epub 2010 May 25.

10.

Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial.

Bobe G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Colburn NH, Cross AJ.

Cancer Prev Res (Phila). 2010 Jun;3(6):764-75. doi: 10.1158/1940-6207.CAPR-09-0161. Epub 2010 May 18.

11.

Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.

Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, Sandler RS, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JA.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2726-33. doi: 10.1158/1055-9965.EPI-09-0363. Epub 2009 Sep 15.

12.

The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence.

Sansbury LB, Wanke K, Albert PS, Kahle L, Schatzkin A, Lanza E; Polyp Prevention Trial Study Group.

Am J Epidemiol. 2009 Sep 1;170(5):576-84. doi: 10.1093/aje/kwp169. Epub 2009 Jul 30.

13.

Hyperplastic polyps and the risk of adenoma recurrence in the polyp prevention trial.

Laiyemo AO, Murphy G, Sansbury LB, Wang Z, Albert PS, Marcus PM, Schoen RE, Cross AJ, Schatzkin A, Lanza E.

Clin Gastroenterol Hepatol. 2009 Feb;7(2):192-7. doi: 10.1016/j.cgh.2008.08.031. Epub 2008 Sep 3.

14.

Dietary flavonoids and colorectal adenoma recurrence in the Polyp Prevention Trial.

Bobe G, Sansbury LB, Albert PS, Cross AJ, Kahle L, Ashby J, Slattery ML, Caan B, Paskett E, Iber F, Kikendall JW, Lance P, Daston C, Marshall JR, Schatzkin A, Lanza E.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1344-53. doi: 10.1158/1055-9965.EPI-07-0747.

15.

Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years.

Laiyemo AO, Murphy G, Albert PS, Sansbury LB, Wang Z, Cross AJ, Marcus PM, Caan B, Marshall JR, Lance P, Paskett ED, Weissfeld J, Slattery ML, Burt R, Iber F, Shike M, Kikendall JW, Lanza E, Schatzkin A.

Ann Intern Med. 2008 Mar 18;148(6):419-26.

PMID:
18347350
16.

Folate and MTHFR: risk of adenoma recurrence in the Polyp Prevention Trial.

Murphy G, Sansbury LB, Cross AJ, Stolzenberg-Solomon R, Laiyemo A, Albert PS, Wang Z, Schatzkin A, Lehman T, Kalidindi A, Modali R, Lanza E.

Cancer Causes Control. 2008 Sep;19(7):751-8. doi: 10.1007/s10552-008-9137-6. Epub 2008 Mar 6.

PMID:
18322814
17.

A longitudinal study of infant feeding and obesity throughout life course.

Michels KB, Willett WC, Graubard BI, Vaidya RL, Cantwell MM, Sansbury LB, Forman MR.

Int J Obes (Lond). 2007 Jul;31(7):1078-85. Epub 2007 Apr 24.

PMID:
17452993
18.

Nutrition and cancer prevention: targets, strategies, and the importance of early life interventions.

Hursting SD, Cantwell MM, Sansbury LB, Forman MR.

Nestle Nutr Workshop Ser Pediatr Program. 2006;57:153-202. Review. No abstract available.

PMID:
16632966
19.

Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial.

Sansbury LB, Bergen AW, Wanke KL, Yu B, Caporaso NE, Chatterjee N, Ratnasinghe L, Schatzkin A, Lehman TA, Kalidindi A, Modali R, Lanza E.

Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):494-501.

20.

COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States).

Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO, de Cotret AR, Player J, Sandler RS.

Cancer Causes Control. 2006 Apr;17(3):257-66.

PMID:
16489533
21.

Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites.

Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS.

Am J Epidemiol. 2005 Sep 15;162(6):548-58. Epub 2005 Aug 10.

PMID:
16093288
22.

Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm).

Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, Ollila DW.

Ann Surg Oncol. 2004 Oct;11(10):900-6. Epub 2004 Sep 20.

PMID:
15383424
23.

Physicians' use of nonphysician healthcare providers for colorectal cancer screening.

Sansbury LB, Klabunde CN, Mysliwiec P, Brown ML.

Am J Prev Med. 2003 Oct;25(3):179-86.

PMID:
14507523
24.

Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer.

Stitzenberg KB, Calvo BF, Iacocca MV, Neelon BH, Sansbury LB, Dressler LG, Ollila DW.

Am J Clin Pathol. 2002 May;117(5):729-37.

PMID:
12090421

Supplemental Content

Loading ...
Support Center